Rheumatoid arthritis is a long-term autoimmune disorder that primarily affects joints. Credit: stevepb / Pixabay.

The US Food and Drug Administration (FDA) has approved Cumberland Pharmaceuticals’ methotrexate products to treat adult and paediatric patients with rheumatoid arthritis, as well as adults with psoriasis.

To secure the approval for the RediTrex product line, Cumberland communicated with the FDA various times, making several amendments to the new drug application (NDA) submitted to the US regulator in late 2018.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the US, methotrexate is approved as both an oral and injectable treatment. In comparison to oral formulations, injectable methotrexate results in increased efficacy, better continuation rates and less discomfort for patients.

Cumberland’s methotrexate products offer improvements and patient benefits when compared to conventional injectable methotrexate products presently available in the US.

The company has secured exclusive US commercial rights to European pharmaceutical company Nordic Group’s injectable methotrexate line of products.

Cumberland Pharmaceuticals CEO AJ Kazimi said: “We are delighted by the FDA approval of RediTrex for the United States.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are looking forward to bringing this important product to the patients seeking an easy-to-use methotrexate injectable.”

Cumberland is set to introduce two injectable methotrexate product lines within the US to treat active rheumatoid arthritis, juvenile idiopathic arthritis and severe psoriasis.

Cumberland acquires, develops and commercialises branded prescription products to enhance quality of care and address unmet medical requirements.

The company also makes its products available to patients globally via select partnerships.

Some of the company’s portfolio of FDA approved brands include Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, as well as Caldolor (ibuprofen) Injection, for the treatment of pain and fever and Kristalose (lactulose) Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation.